T Halmos|F Salamon - JoVE Visualize

Showing results (41-50 of 52) with videos related to

Pageof 6

Sort By:

Diabetologia|January 1, 1993

Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitusA Császár, H Dieplinger, C Sandholzer, et al.

Diabetologia|July 8, 2005

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic populationB Fagerberg, S Edwards, T Halmos, et al.

Pathology Oncology Research : POR|February 20, 2013

Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessmentK Dede, T Mersich, I Besznyák, et al.

Diabetes Research and Clinical Practice|January 30, 1999

Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesityG Winkler, F Salamon, G Harmos, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Peptide-based inhibitors of the hepatitis C virus serine proteaseM Llinàs-Brunet, M Bailey, G Fazal, et al.

Thrombosis and Haemostasis|November 29, 2013

The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancerZ Baranyai, M Krzystanek, V Jósa, et al.

Bioorganic & Medicinal Chemistry Letters|October 31, 2000

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitorsM Llinàs-Brunet, M Bailey, G Fazal, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine proteaseM Llinàs-Brunet, M Bailey, R Déziel, et al.

Orvosi Hetilap|January 25, 2000

[Detection of antibodies against pancreatic islet cells in clinical practice]P Pánczél, O Külkey, A Luczay, et al.

Orvosi Hetilap|January 5, 2002

[Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin]P Pánczél, N Hosszúfalusi, B Bornemisza, et al.

Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:

Pageof 6

Diabetologia|January 1, 1993

Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitusA Császár, H Dieplinger, C Sandholzer, et al.

Diabetologia|July 8, 2005

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic populationB Fagerberg, S Edwards, T Halmos, et al.

Pathology Oncology Research : POR|February 20, 2013

Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessmentK Dede, T Mersich, I Besznyák, et al.

Diabetes Research and Clinical Practice|January 30, 1999

Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesityG Winkler, F Salamon, G Harmos, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Peptide-based inhibitors of the hepatitis C virus serine proteaseM Llinàs-Brunet, M Bailey, G Fazal, et al.

Thrombosis and Haemostasis|November 29, 2013

The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancerZ Baranyai, M Krzystanek, V Jósa, et al.

Bioorganic & Medicinal Chemistry Letters|October 31, 2000

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitorsM Llinàs-Brunet, M Bailey, G Fazal, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine proteaseM Llinàs-Brunet, M Bailey, R Déziel, et al.

Orvosi Hetilap|January 25, 2000

[Detection of antibodies against pancreatic islet cells in clinical practice]P Pánczél, O Külkey, A Luczay, et al.

Orvosi Hetilap|January 5, 2002

[Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin]P Pánczél, N Hosszúfalusi, B Bornemisza, et al.

Pageof 6